Johnson & Johnson Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes
May 30, 2024
May 30, 2024
TITUSVILLE, New Jersey, May 30 (TNSres) -- Johnson & Johnson issued the following news release:
* * *
* Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major depressive disorder (MDD) with insomnia symptoms, as presented at ASCP 2024
* Approximately 60 percent of MDD patients on standard-of-care oral antidepressants experience residual insomnia symptoms/1, undersco . . .
* * *
* Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major depressive disorder (MDD) with insomnia symptoms, as presented at ASCP 2024
* Approximately 60 percent of MDD patients on standard-of-care oral antidepressants experience residual insomnia symptoms/1, undersco . . .